The retrospective study of cost-effectiveness for prophylactic and on-demand treatment of the pediatric patients with hemophilia A in Iran

Cover Page

Cite item

Full Text

Abstract

Hemophilia is the second most common inherited bleeding disorder after von Willebrand disease. Delayed clotting is usually observed in all main types of hemophilia caused by deficiencies in blood coagulation factors. Primary prophylaxis is considered the gold standard to prevent acute hemarthrosis and chronic arthropathy in patients with severe hemophilia A. However, some low-income countries, like Iran, have to prioritize access to preventive care to balance the financial resources and per capita access to coagulation factors. In order to compare the cost-effectiveness of on-demand and preventive treatment, we conducted a retrospective study on 55 patients with hemophilia A. We collected data from two groups of patients: those who had received routine prophylactic treatment and those who had received on-demand (episodic) treatment. The results of our study revealed a significant difference in the annualized bleeding rates (ABRs) between the two groups: ABR in the prophylactic treatment group was lower than in the on-demand treatment group (2.19 vs 7.25). In addition, we found substantial differences between the prophylactic and on-demand treatment groups in the number of hospital visits per year (9.8 vs 14.41), the annual number of infusions (107.35 vs 229.58), and in the mean cost of treatment (30.96€ vs 63€). In conclusion, prophylactic therapy seems to be more effective than on-demand treatment. This study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1398.456). Written informed consent was obtained from the patients’ parents.

About the authors

Tina Alidoust

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Email: dr.alidoust@gmail.com

Ahvaz

Iran, Islamic Republic of

Mohammad Bahadoram

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Email: Mohammadbahadoram@yahoo.com
ORCID iD: 0000-0002-7106-9799

Ahvaz

Iran, Islamic Republic of

Arash Alghasi

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Email: arashalqasi@yahoo.com
ORCID iD: 0000-0003-3482-2195

Ahvaz

Iran, Islamic Republic of

Mohammad-Reza Mahmoudian-Sani

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Email: mohamadsani495@gmail.com
ORCID iD: 0000-0002-1096-5661

Ahvaz

Iran, Islamic Republic of

Esma’il Akade

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Email: eakadeh@gmail.com
ORCID iD: 0000-0001-7722-0165

Ahvaz

Iran, Islamic Republic of

Hamid Nilsaz-Dezfouli

Department of industrial Engineering, Mahshahr Branch, Islamic Azad University

Email: keikhaeib@yahoo.com

Mahshahr

Iran, Islamic Republic of

Bijan Keikhaei

Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences

Author for correspondence.
Email: keikhaeib@yahoo.com
ORCID iD: 0000-0002-3087-7650

Dr. Bijan Keikhaei Address: Golestan Highway

Ahvaz

Iran, Islamic Republic of

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Alidoust T., Bahadoram M., Alghasi A., Mahmoudian-Sani M., Akade E., Nilsaz-Dezfouli H., Keikhaei B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.